Product profile
Reta
Overview
A synthetic triple agonist peptide targeting GLP-1, GIP, and glucagon receptors, researched for integrated metabolic signaling, glucose regulation, and energy balance pathways.
- Concentration
- 10 mg / 20 mg / 40 mg
- Stock
- Out of stock
Product details
Reta is a synthetic peptide engineered as a triple receptor agonist simultaneously targeting glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors, with structural modifications including fatty acid conjugation for stability.
- Receptor Targets: GLP-1, GIP, glucagon (triple agonist)
- Key Feature: Fatty diacid moiety for pharmacokinetics
- Research Focus Areas: Synergistic incretin/glucagon effects, liver fat dynamics, weight-related metabolism
- Common Models: Rodent obesity/diabetes paradigms, MASLD/MASH studies
- Mechanistic Interests: Multi-receptor activation, insulin/glucagon balance
It is used in research to study integrated metabolic signaling networks, glucose homeostasis, appetite regulation circuits, energy expenditure pathways, and multi-hormonal effects in experimental obesity and metabolic disorder models.
All products currently listed on this site are for research purposes only.
